Furthermore, ZEB1 is considered one of the key genes closely associated with the poor clinical presentation and outcomes of DLBCL, and its aberrant expression often indicates a poorer prognosis (Lemma et al., 2013). Here, ZEB1 is linked to diffuse large B-cell lymphoma.